Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Acta Odontol Scand ; 76(2): 148-152, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29125000

ABSTRACT

BACKGROUND AND OBJECTIVE: radioiodine treatment (I131) used to treat thyroid carcinomas produces side effects (sialadenitis, xerostomia, dysphagia and caries susceptibility) reflecting in a poor patient quality of life. This study aimed to evaluate the effect of I131 on salivary function and possible oral impairment. MATERIAL AND METHODS: Thirty-seven patients undergoing I131 were submitted to oral examination, answer questions regarding xerostomia/hyposalivation and collect saliva at three moments (M1: 30-45 days before I131, M2: 1-2 days after I131 and M3: 7-10 days after treatment). Saliva was assayed for flow rate and calcium/phosphate concentrations. RESULTS AND CONCLUSIONS: significant difference in calcium/phosphate concentration was shown between M1 and M2, with evident decrease at M2. Flow rate reduced right after treatment with 41% of patients returning to previous rate at M3 (no statistical difference). A higher number of patients related xerostomia and difficulty in swallowing food at M2. The results showed that xerostomia/hyposalivation, dysphagia and calcium/phosphate concentration decrease may be considered early radioiodine side effects.


Subject(s)
Carcinoma, Papillary/radiotherapy , Iodine Radioisotopes/adverse effects , Saliva/radiation effects , Salivary Glands/radiation effects , Thyroid Neoplasms/radiotherapy , Adult , Aged , Deglutition Disorders/physiopathology , Female , Humans , Male , Middle Aged , Quality of Life , Salivary Glands/drug effects , Sialadenitis/etiology , Xerostomia/chemically induced , Xerostomia/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...